Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

Dean F. Bajorin, Paul M. Dodd, Madhu Mazumdar, Melissa Fazzari, John A. McCaffrey, Howard I. Scher, Harry Herr, Geralyn Higgins, Mary G. Boyle

Research output: Contribution to journalArticle

509 Citations (Scopus)

Abstract

Purpose: The variation in reported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatment patient characteristics. We hypothesized that a prognostic factor-based model of survival among patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy could account for such differences and help guide clinical trial design and interpretation. Patients and Methods: A database of 203 patients with unresectable or metastatic TCC was retrospectively subjected to a multivariate regression analysis to determine which patient characteristics had independent prognostic significance for survival. Patients were assigned to three risk categories depending on the number of unfavorable characteristics. Patient selection in phase II studies was addressed by developing a table of expected median survival for patient cohorts that had varying proportions of patients from the three risk categories. Results: Two factors had independent prognosis: Karnofsky performance status (KPS) less than 80% and visceral (lung, liver, or bone) metastasis. Median survival times for patients who had zero, one, or two risk factors were 33, 13.4, and 9.3 months, respectively (P = .0001). The median survival time of patient cohorts could vary from 9 to 26 months simply by altering the proportion of patients from different risk categories. Conclusion: The presence of baseline KPS less than 80% or visceral metastasis has an impact on survival. Reporting the proportion of patients with zero, one, and two risk factors will facilitate understanding of the relevance of the median survival in phase II trials. Phase III trials should stratify patients according to the number of risk factors to avoid imbalance in treatment arms.

Original languageEnglish (US)
Pages (from-to)3173-3181
Number of pages9
JournalJournal of Clinical Oncology
Volume17
Issue number10
DOIs
StatePublished - Oct 1999
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Survival
Therapeutics
Karnofsky Performance Status
Neoplasm Metastasis
Drug Therapy
Vinblastine
Methotrexate
Doxorubicin
Patient Selection
Cisplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. / Bajorin, Dean F.; Dodd, Paul M.; Mazumdar, Madhu; Fazzari, Melissa; McCaffrey, John A.; Scher, Howard I.; Herr, Harry; Higgins, Geralyn; Boyle, Mary G.

In: Journal of Clinical Oncology, Vol. 17, No. 10, 10.1999, p. 3173-3181.

Research output: Contribution to journalArticle

Bajorin, DF, Dodd, PM, Mazumdar, M, Fazzari, M, McCaffrey, JA, Scher, HI, Herr, H, Higgins, G & Boyle, MG 1999, 'Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy', Journal of Clinical Oncology, vol. 17, no. 10, pp. 3173-3181. https://doi.org/10.1200/JCO.1999.17.10.3173
Bajorin, Dean F. ; Dodd, Paul M. ; Mazumdar, Madhu ; Fazzari, Melissa ; McCaffrey, John A. ; Scher, Howard I. ; Herr, Harry ; Higgins, Geralyn ; Boyle, Mary G. / Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 10. pp. 3173-3181.
@article{345ed92f64a943bab70ef9d44da1aa9f,
title = "Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy",
abstract = "Purpose: The variation in reported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatment patient characteristics. We hypothesized that a prognostic factor-based model of survival among patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy could account for such differences and help guide clinical trial design and interpretation. Patients and Methods: A database of 203 patients with unresectable or metastatic TCC was retrospectively subjected to a multivariate regression analysis to determine which patient characteristics had independent prognostic significance for survival. Patients were assigned to three risk categories depending on the number of unfavorable characteristics. Patient selection in phase II studies was addressed by developing a table of expected median survival for patient cohorts that had varying proportions of patients from the three risk categories. Results: Two factors had independent prognosis: Karnofsky performance status (KPS) less than 80{\%} and visceral (lung, liver, or bone) metastasis. Median survival times for patients who had zero, one, or two risk factors were 33, 13.4, and 9.3 months, respectively (P = .0001). The median survival time of patient cohorts could vary from 9 to 26 months simply by altering the proportion of patients from different risk categories. Conclusion: The presence of baseline KPS less than 80{\%} or visceral metastasis has an impact on survival. Reporting the proportion of patients with zero, one, and two risk factors will facilitate understanding of the relevance of the median survival in phase II trials. Phase III trials should stratify patients according to the number of risk factors to avoid imbalance in treatment arms.",
author = "Bajorin, {Dean F.} and Dodd, {Paul M.} and Madhu Mazumdar and Melissa Fazzari and McCaffrey, {John A.} and Scher, {Howard I.} and Harry Herr and Geralyn Higgins and Boyle, {Mary G.}",
year = "1999",
month = "10",
doi = "10.1200/JCO.1999.17.10.3173",
language = "English (US)",
volume = "17",
pages = "3173--3181",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

AU - Bajorin, Dean F.

AU - Dodd, Paul M.

AU - Mazumdar, Madhu

AU - Fazzari, Melissa

AU - McCaffrey, John A.

AU - Scher, Howard I.

AU - Herr, Harry

AU - Higgins, Geralyn

AU - Boyle, Mary G.

PY - 1999/10

Y1 - 1999/10

N2 - Purpose: The variation in reported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatment patient characteristics. We hypothesized that a prognostic factor-based model of survival among patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy could account for such differences and help guide clinical trial design and interpretation. Patients and Methods: A database of 203 patients with unresectable or metastatic TCC was retrospectively subjected to a multivariate regression analysis to determine which patient characteristics had independent prognostic significance for survival. Patients were assigned to three risk categories depending on the number of unfavorable characteristics. Patient selection in phase II studies was addressed by developing a table of expected median survival for patient cohorts that had varying proportions of patients from the three risk categories. Results: Two factors had independent prognosis: Karnofsky performance status (KPS) less than 80% and visceral (lung, liver, or bone) metastasis. Median survival times for patients who had zero, one, or two risk factors were 33, 13.4, and 9.3 months, respectively (P = .0001). The median survival time of patient cohorts could vary from 9 to 26 months simply by altering the proportion of patients from different risk categories. Conclusion: The presence of baseline KPS less than 80% or visceral metastasis has an impact on survival. Reporting the proportion of patients with zero, one, and two risk factors will facilitate understanding of the relevance of the median survival in phase II trials. Phase III trials should stratify patients according to the number of risk factors to avoid imbalance in treatment arms.

AB - Purpose: The variation in reported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatment patient characteristics. We hypothesized that a prognostic factor-based model of survival among patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy could account for such differences and help guide clinical trial design and interpretation. Patients and Methods: A database of 203 patients with unresectable or metastatic TCC was retrospectively subjected to a multivariate regression analysis to determine which patient characteristics had independent prognostic significance for survival. Patients were assigned to three risk categories depending on the number of unfavorable characteristics. Patient selection in phase II studies was addressed by developing a table of expected median survival for patient cohorts that had varying proportions of patients from the three risk categories. Results: Two factors had independent prognosis: Karnofsky performance status (KPS) less than 80% and visceral (lung, liver, or bone) metastasis. Median survival times for patients who had zero, one, or two risk factors were 33, 13.4, and 9.3 months, respectively (P = .0001). The median survival time of patient cohorts could vary from 9 to 26 months simply by altering the proportion of patients from different risk categories. Conclusion: The presence of baseline KPS less than 80% or visceral metastasis has an impact on survival. Reporting the proportion of patients with zero, one, and two risk factors will facilitate understanding of the relevance of the median survival in phase II trials. Phase III trials should stratify patients according to the number of risk factors to avoid imbalance in treatment arms.

UR - http://www.scopus.com/inward/record.url?scp=0032887956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032887956&partnerID=8YFLogxK

U2 - 10.1200/JCO.1999.17.10.3173

DO - 10.1200/JCO.1999.17.10.3173

M3 - Article

C2 - 10506615

AN - SCOPUS:0032887956

VL - 17

SP - 3173

EP - 3181

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -